&lt;p&gt;Anti-MAdCAM-1-Conjugated Nanocarriers Delivering Quantum Dots Enable Specific Imaging of Inflammatory Bowel Disease&lt;/p&gt;

Truffi, Marta; Sevieri, Marta; Morelli, Lucia; Monieri, Matteo; Mazzucchelli, Serena; Sorrentino, Luca; Allevi, Raffaele; Bonizzi, Arianna; Zerbi, Pietro; Marchini, Beatrice; Longhi, Erika; Sampietro, Gianluca; Colombo, Francesco; Prosperi, Davide; Colombo, Miriam; Corsi, Fabio

doi:10.2147/ijn.s264513

Cited by 10 publications

(5 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These NPs were intravenously injected into IBD mice. The T1-weighted images obtained after 24 h showed enhancement in the rectal mucosa, proving the specific localization of PLGA NPs [ 107 ]. This technique mimics the behavior of circulating leukocytes during inflammation and allows for the tracking of their interaction with adhesion molecules whose expression is enhanced during inflammatory conditions.…”

Section: Inflammatory Bowel Diseasementioning

confidence: 99%

Use of Poly Lactic-co-glycolic Acid Nano and Micro Particles in the Delivery of Drugs Modulating Different Phases of Inflammation

et al. 2023

View full text Add to dashboard Cite

Chronic inflammation contributes to the pathogenesis of many diseases, including apparently unrelated conditions such as metabolic disorders, cardiovascular diseases, neurodegenerative diseases, osteoporosis, and tumors, but the use of conventional anti-inflammatory drugs to treat these diseases is generally not very effective given their adverse effects. In addition, some alternative anti-inflammatory medications, such as many natural compounds, have scarce solubility and stability, which are associated with low bioavailability. Therefore, encapsulation within nanoparticles (NPs) may represent an effective strategy to enhance the pharmacological properties of these bioactive molecules, and poly lactic-co-glycolic acid (PLGA) NPs have been widely used because of their high biocompatibility and biodegradability and possibility to finely tune erosion time, hydrophilic/hydrophobic nature, and mechanical properties by acting on the polymer’s composition and preparation technique. Many studies have been focused on the use of PLGA-NPs to deliver immunosuppressive treatments for autoimmune and allergic diseases or to elicit protective immune responses, such as in vaccination and cancer immunotherapy. By contrast, this review is focused on the use of PLGA NPs in preclinical in vivo models of other diseases in which a key role is played by chronic inflammation or unbalance between the protective and reparative phases of inflammation, with a particular focus on intestinal bowel disease; cardiovascular, neurodegenerative, osteoarticular, and ocular diseases; and wound healing.

show abstract

Section: Inflammatory Bowel Diseasementioning

confidence: 99%

Use of Poly Lactic-co-glycolic Acid Nano and Micro Particles in the Delivery of Drugs Modulating Different Phases of Inflammation

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Imaging has long been utilized to evaluate segments of the digestive tract that are inaccessible with conventional endoscopy. For decades, nanoparticles such as Au, 116 , 117 Fe and Au complexes, 118 quantum dots, 119 , 120 MnO, 82 and lipid nanoparticles 74 have been developed and used in cancer imaging and diagnosis. During traditional clinical CT imaging, iodinated small molecules and barium sulfate suspensions are usually used as contrast agents, 121 , 122 but they are not ideal for imaging IBD due to their nonspecificity.…”

Section: Nanocarriers Mediate Precise Diagnoses Of Ibdmentioning

confidence: 99%

“…In another study, Fabio Corsi and coworkers loaded quantum dots into anti-MAdCAM-1 coupled PLGA-PEG nanoparticles (P@QD-MdC NPs). 120 Upon intravenous injection, the system is expected to specifically bind to MAdCAM-1 protein on the apical side of mucosal endothelial vessels and penetrate the bowel mucosa. In vivo experiments showed progressive P@QD-MdC NP accumulation in the inflamed colon and provided an enhanced and localized signal.…”

Section: Nanocarriers Mediate Precise Diagnoses Of Ibdmentioning

confidence: 99%

Recent Progress in the Diagnosis and Precise Nanocarrier-Mediated Therapy of Inflammatory Bowel Disease

Wang¹,

Yu²,

Yang³

2021

JIR

View full text Add to dashboard Cite

The effective colon drug delivery remains to be an international frontier research in inflammatory bowel disease (IBD) therapy. The exploration and research of nanocarrier-based nanomedicine with great potential brings new opportunities for IBD therapy and diagnoses. Functional nanocarriers with varying morphology and characteristics can not only effectively avoid the destruction of the complex gastrointestinal (GI) tract microenvironment but also endow drugs with target therapy and improved bioavailability, thus elevating therapeutic efﬁcacy. In this review, we illustrated several challenges in IBD therapy, then emphasis on some latest research progress of nanoparticles based therapy of oral administration, rectal administration and parenteral administration, as well as IBD diagnoses. Finally, we described the future perspective of nanocarriers in the treatment and diagnoses of IBD.

show abstract

“…In the context of nanoparticles properly designed for the use as MRI contrast agents, it is worth mentioning the work of Truffi et al [ 43 ]. They prepared poly(lactic-co-glycolic acid)-block-b-poly(ethyleneglycol) (PLGA-PEG) polymer micelles targeted to the endothelial mucosal addressin cell adhesion molecule 1 (MAdCAM-1), conjugated with the half-chain of a monoclonal MAdCAM-1 antibody.…”

Section: Main Technological Strategies and Examples Of Imaging Agents Developed For Improving Diagnostic Efficiencymentioning

confidence: 99%

The Pharmaceutical Technology Approach on Imaging Innovations from Italian Research

et al. 2021

View full text Add to dashboard Cite

Many modern therapeutic approaches are based on precise diagnostic evidence, where imaging procedures play an essential role. To date, in the diagnostic field, a plethora of agents have been investigated to increase the selectivity and sensitivity of diagnosis. However, the most common drawbacks of conventional imaging agents reside in their non-specificity, short imaging time, instability, and toxicity. Moreover, routinely used diagnostic agents have low molecular weights and consequently a rapid clearance and renal excretion, and this represents a limitation if long-lasting imaging analyses are to be conducted. Thus, the development of new agents for in vivo diagnostics requires not only a deep knowledge of the physical principles of the imaging techniques and of the physiopathological aspects of the disease but also of the relative pharmaceutical and biopharmaceutical requirements. In this scenario, skills in pharmaceutical technology have become highly indispensable in order to respond to these needs. This review specifically aims to collect examples of newly developed diagnostic agents connoting the importance of an appropriate formulation study for the realization of effective products. Within the context of pharmaceutical technology research in Italy, several groups have developed and patented promising agents for fluorescence and radioactive imaging, the most relevant of which are described hereafter.

show abstract

<p>Anti-MAdCAM-1-Conjugated Nanocarriers Delivering Quantum Dots Enable Specific Imaging of Inflammatory Bowel Disease</p>

Cited by 10 publications

References 38 publications

Use of Poly Lactic-co-glycolic Acid Nano and Micro Particles in the Delivery of Drugs Modulating Different Phases of Inflammation

Use of Poly Lactic-co-glycolic Acid Nano and Micro Particles in the Delivery of Drugs Modulating Different Phases of Inflammation

Recent Progress in the Diagnosis and Precise Nanocarrier-Mediated Therapy of Inflammatory Bowel Disease

The Pharmaceutical Technology Approach on Imaging Innovations from Italian Research

Contact Info

Product

Resources

About